Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses

被引:21
作者
Bennouna, J
Hildesheim, A
Chikamatsu, K
Gooding, W
Storkus, WJ
Whiteside, TL
机构
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA
[2] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[3] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA
[4] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA
关键词
ELISPOT assay; IL-5; T-cell frequency; helper T cells;
D O I
10.1016/S0022-1759(01)00566-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To be able to determine the frequencies of helper-type T lymphocyte (Th) precursors specific for viral or tumor-associated antigens, an ELISPOT assay for IL-5 production was developed. The assay reproducibility was first determined using fresh or cryopreserved peripheral blood mononuclear cells (PBMC) obtained from six normal donors and tested for IL-5 production after 48 h stimulation with phytohemagglutinin (PHA). Both inter-assay (within-subject CV = 1.6%) and intra-assay (within-subject CV = 0.8%) variabilities were found to be acceptable, and the frequencies of IL-5 secreting cells were comparable in cryopreserved and fresh PBMC of the same donors. The presence and frequency of Th precursor cells to viral capsid L I protein (viral-like particles, VLP-L1) of human papillomavirus type 16 (HPV-16) in PBMC obtained from seven non-immunized donors and two volunteers immunized with VLP-L1 were then evaluated. Using autologous dendritic cells as antigen-presenting cells (APC) for VLP-L1 in direct 48-h ELISPOT assays, the mean frequency of IL-5 secreting CD4+ T cells was found to be < 1/10(5) (negative) in normal donors but was 1/2, 436 and 1/3678 in the two volunteers immunized with VLP-L1. The assay is applicable to monitoring of the frequency of antigen-specific T cells in the peripheral circulation of individuals immunized with HPV-derived antigens. To test the assay utility in the assessment of Th tumor-reactive lymphocytes, we also used it to determine the frequency of the wild-type sequence (wt) p53(22-36) peptide-specific, HLA-DR4-restricted T cells in the bulk CD4+ T cell line. This frequency was 1/33. The ELISPOT assay for IL-5 production can be reliably used to measure Th-type responses in a variety of experimental settings. (C) 2002 Elsevier Science B.V. All lights reserved.
引用
收藏
页码:145 / 156
页数:12
相关论文
共 28 条
  • [1] ALLIONE A, 1994, CANCER RES, V54, P6022
  • [2] Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
    Asai, T
    Storkus, WJ
    Whiteside, TL
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2000, 7 (02) : 145 - 154
  • [3] BERTOLETTI A, 1997, GASTROENTEROLOGY, V113, P1050
  • [4] Chikamatsu Kazuaki, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P278
  • [5] MECHANISMS OF HELPER T-CELL REGULATION OF B-CELL ACTIVITY
    COFFMAN, RL
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 681 : 25 - 28
  • [6] T-HELPER SUBSET INVOLVEMENT IN 2 HIGH ANTIBODY RESPONDER LINES OF MICE (BIOZZI MICE) - HI (SUSCEPTIBLE) AND HII (RESISTANT) TO COLLAGEN-INDUCED ARTHRITIS
    DEFRANCO, M
    GILLEPERRAMANT, MF
    MEVEL, JC
    COUDERC, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (01) : 132 - 136
  • [7] DELPRETE G, 1994, LAB INVEST, V70, P299
  • [8] DISIS ML, 1994, CANCER RES, V54, P16
  • [9] A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers
    Evans, TG
    Bonnez, W
    Rose, RC
    Koenig, S
    Demeter, L
    Suzich, JA
    O'Brien, D
    Campbell, M
    White, WI
    Balsley, J
    Reichman, RC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (10) : 1485 - 1493
  • [10] Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
    Harro, CD
    Pang, YYS
    Roden, RBS
    Hildesheim, A
    Wang, ZH
    Reynolds, MJ
    Mast, TC
    Robinson, R
    Murphy, BR
    Karron, RA
    Dillner, J
    Schiller, JT
    Lowy, DR
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04): : 284 - 292